# A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants

> **NCT07413367** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Tonix Pharmaceuticals, Inc.** · enrollment: 50 (actual)

## Conditions studied

- Pharmakokinetic
- Open Label
- Phase 1

## Interventions

- **DRUG:** TNX-102 SL Tablet

## Key facts

- **NCT ID:** NCT07413367
- **Lead sponsor:** Tonix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-12-09
- **Primary completion:** 2026-02-10
- **Final completion:** 2026-02-10
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07413367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07413367, "A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07413367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*